Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug ...

The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the ...

Combination may offer a substitute to basal-bolus insulin in people with type 2 diabetes inadequately controlled with daily basal insulin.

The phase 3 SURPASS-4 trial published in 2021 established that tirzepatide lowers blood sugar and supports weight loss better ...

The phase 3 SURPASS-4 trial published in 2021 established that tirzepatide lowers blood sugar and supports weight loss better than insulin glargine (a ...

Eli Lilly's efsitora alfa was noninferior to once-daily insulin in type 2 diabetes, but an increased hypoglycemia risk was seen in type 1 diabetes.

The latest clinical trial results from Eli Lilly show the drug manufacturer's once-weekly insulin injection is just as ...

Data from the two Phase III trials showed that once-weekly insulin efsitora induced HbA1C reductions similar to daily insulin ...

Eli Lilly said a once-weekly dose of insulin efsitora proved to reduce hemoglobin A1C in a Qwint-2 Phase 3 trial when compared with a daily dose of insulin in people with type 2 diabetes using insulin ...

If you've recently received a diagnosis of type 2 diabetes, understanding your treatment options is an important first step.

Abbott launched an over-the-counter continuous glucose monitoring system, Lingo, for adults not on insulin -- the second such ...